Score Overview
PeriodNet IncomeRevenueScoreGrowthTrendConsistencyGrowthTrendConsistency
5 Years
3.1
-199.00%
40%
—
44.15%
40%
—
5 Years
Score3.1
Net Growth-199.00%
Net Trend40%
Net Income Consistency—
Rev Growth44.15%
Rev Trend40%
Revenue Consistency—
Kymera Therapeutics Inc fundamental performance
Between 2020 and 2025, revenue grew from $ 34M to $ 39M and net income went from -$ 45M to -$ 311M. Revenue increased in 2 of those 5 years; net income in 2.
Kymera Therapeutics Inc currently holds a 5-year HDB Score of 3.1 out of 10. How the HDB Score is calculated.
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-08-12 | $ 114.03 | — |
1 Year2025-08-12 | $ 39.87 | 186.00% |
5 Years2021-08-12 | $ 54.97 | 107.44% |
All Time2020-08-21 | $ 33.26 | 242.84% |
| Period | Last Price2026-08-12 | 1 Year2025-08-12 | 5 Years2021-08-12 | All Time2020-08-21 |
|---|---|---|---|---|
| Price | $ 114.03 | $ 39.87 | $ 54.97 | $ 33.26 |
| Return | — | 186.00% | 107.44% | 242.84% |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
| Year | |||
|---|---|---|---|
| 2026 | $ 104M | -$ 299M | $ 690M |
| 2025 | $ 39M | -$ 311M | $ 848M |
| 2024 | $ 47M | -$ 223M | $ 488M |
| 2023 | $ 78M | -$ 146M | $ 374M |
| 2022 | $ 46M | -$ 154M | $ 407M |
| 2021 | $ 72M | -$ 100M | $ 442M |
| IPO2020 | $ 34M | -$ 45M | $ 296M |
Explore beyond KYMR
You're looking at Kymera Therapeutics Inc. Members apply the same fundamental framework across all 3,860 companies we cover.
- Every HDB Score — 1, 5, 10, 20 and 30 years, plus all-time
- Revenue and Net Income Consistency for every period
- Rank all 3,860 companies by any metric, not just three
- Filter by sector and currency, and page through the whole list
- Track your holdings in a portfolio
$99/year $149 founding price
Unlock Holder Dashboard30-day money-back guarantee.
